Bill Summary for H 934 (2019-2020)
|View NCGA Bill Details||2019-2020 Session|
AN ACT EXPANDING THE RIGHT TO TRY ACT TO PROVIDE ACCESS TO INVESTIGATIONAL ADULT STEM CELL TREATMENTS FOR PATIENTS DIAGNOSED WITH A TERMINAL OR CHRONIC ILLNESS.Intro. by Blackwell, Lambeth, Murphy, Reives.
|View: All Summaries for Bill||Tracking:|
Senate committee substitute to the 2nd edition makes the following changes.
Amends new GS 90-325.12, by requiring that investigational adult stem cell treatment, as authorized, be provided at an accredited medical school located in the state, an affiliated facility of an accredited medical school located in the state, or any other facility approved by the institutional review board overseeing the treatment (previously, allowed for treatment at a licensed hospital, a licensed ambulatory surgical center, or an accredited medical school located in the state). Amends new GS 90-325.13, by requiring an institutional review board overseeing investigational adult stem cell treatments be affiliated with an accredited medical school located in the state or an affiliated facility of a medical school located in the state (previously, required affiliation with an accredited medical school in the state or a licensed hospital with at least 150 beds).
Amends new GS 90-325.14, which prohibits the purchase and sale of adult stem cells for certain investigational treatments, by excepting from the prohibition health care providers, medical researchers, or biosciences professionals who are either (1) engaged in research, clinical trials, or investigational adult stem cell treatment being overseen or having been approved by an institutional review board meeting the specified requirements or (2) otherwise engaged in legal research, clinical trials, or investigational adult stem cell research. Makes conforming changes.